# Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

Study · id `cardio:ct-nct02430350` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02430350](<https://clinicaltrials.gov/study/NCT02430350>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02430350

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1200 participants.

## Technical summary

Registry record NCT02430350. Randomized; quadruple masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2016-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1200 participants (enrolled count; ClinicalTrials.gov record NCT02430350, source copy `cardio:ctgov-nct02430350-2017-01-16`, retrieved 2026-10-26)
- Start date: 2015-05 (registry gives no type) (ClinicalTrials.gov record NCT02430350, source copy `cardio:ctgov-nct02430350-2017-01-16`, retrieved 2026-10-26)
- Primary completion: 2016-12 (actual) (ClinicalTrials.gov record NCT02430350, source copy `cardio:ctgov-nct02430350-2017-01-16`, retrieved 2026-10-26)
- Completion: 2016-12 (actual) (ClinicalTrials.gov record NCT02430350, source copy `cardio:ctgov-nct02430350-2017-01-16`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02430350, source copy `cardio:ctgov-nct02430350-2017-01-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02430350-2017-01-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Compound Edaravone Injection
- Intervention (Drug): Edaravone Injection
- Lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. (`cardio:org-jiangsu-simcere-pharmaceutical-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial (`cardio:pubmed-33588596`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 78b016e51246b513b74b13b11d0c42bf61bfebc126fac7496d52ddedbac4f173
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
